Purpose: Spinal cord gliomas are rare, and there is no consensus on the optimal radiotherapy (RT) regimen. Herein, we investigated therapeutic outcomes in spinal cord gliomas to obtain clues for the optimal RT regimen. Methods: We assessed 45 patients who received RT for primary spinal cord non-ependymoma gliomas between 2005 and 2017: 37 (82%) received postoperative RT, 6 (13%) underwent definitive RT without surgery, and 2 (5%) received salvage RT for recurrent tumors. Craniospinal irradiation (CSI; median, 40 Gy) was administered in 4 patients with seeding at diagnosis; all other patients received local RT only (median, 50.4 Gy). Results: In all 23 failures occurred (20 in patients without initial seeding +3 in patients with initial seeding and CSI; median follow-up, 33 months). The 2‑year overall survival and progression-free survival rates were 74 and 54%, respectively. Overall, 13 (32%) new seeding events outside the local RT field developed either first or subsequently. Tumor grade was significantly associated with survival endpoints (p = 0.009, 0.028) and overall seeding rates (p = 0.042). In grade II tumors, seeding developed in 23%, with a dismal prognosis (median, 10 months after RT). In grade III tumors, seeding developed in 45% with diverse prognosis. In grade IV tumors, seeding developed in 45%. The survival of patients with newly developed seeding was significantly worse than the others (2-year 50%, p < 0.001). Conclusion: To encompass a considerable rate of progressive disease seeding, aggressive treatment such as pre-emptive application of CSI needs to be considered for high-grade spinal cord gliomas with adverse features. Prophylactic CSI could be an option for survival prolongation and requires prospective validation.
|Translated title of the contribution||Treatment outcomes of radiotherapy for primary spinal cord glioma|
|Number of pages||11|
|Journal||Strahlentherapie und Onkologie|
|Publication status||Published - 2019 Feb 6|
Bibliographical noteFunding Information:
The abstract of this study was accepted for poster viewing at the 37th Annual Meeting of the the European SocieTy for Radiotherapy & Oncology (ESTRO), Barcelona, Spain, April, 2018, and presented at the Annual Meeting of the Korean Society for Neuro-Oncology (KSNO), Seoul, March 2018. The authors would like to thank Franziska Walter (LMU University Hospital, D-81377, Munich, Germany.) for her help with the German abstract of this manuscript. This work was supported by Ministry of Science, Korea through the R&D program of NRF-2017R1C1B2010379.
Funding This work was supported by Ministry of Science, through the R&D program of NRF-2017R1C1B2010379.
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging